Indietro

Amgen Inc

AM Ticker: AMGN ISIN: US0311621009

Aggiungi al portafoglio Analisi del portafoglio in 2min

Stock Large-cap Dividend payer Trading above 200-day average Near 52-week high

Capitalizzazione

177,71 Mld $

P/E

22,89

Forward P/E

14,81

Profit margin

20,96%

Revenue growth QoQ

5,80%

Div. yield

2,92%

Beta

0,43

442,24 $ -0,36%

Prezzo al 2026-08-25 · NASDAQ

Performance per periodo

Rendimenti cumulativi

1 Month +18,22%

6 Months +16,61%

1 Year +56,95%

5 Years +18,34% p.a.+131,93%

10 Years +13,27% p.a.+247,44%

Since inception +9,80% p.a.+933,03%

Rendimenti per anno

YTD +37,88%

2025 +29,67%

2024 -6,77%

2023 +13,46%

2022 +20,43%

2021 +0,89%

Key stats

Market cap

177,71 Mld

P/E

22,89

Dividend yield

2,92%

Beta

0,43

52-week range

253.48 - 391.29

50-day MA

353,55

200-day MA

325,47

Section 1

Business overview

Company profile data from fundamentals.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is he

Sector Healthcare

Industry Drug Manufacturers - General

Country United States

Exchange NASDAQ

Section 2

Financial quality

Profitability and balance-sheet quality indicators from reported fundamentals.

Profitability

ROE 1,01%

ROA 8,35%

Profit margin 20,96%

Operating margin 33,80%

PEG ratio 2,18

Revenue/share TTM 69,12

Revenue TTM 37,22 Mld

EBITDA 16,92 Mld

Gross profit TTM 26,59 Mld

Beta 0,43

Valuation

Trailing P/E 22,89

Forward P/E 14,81

P/B 19,37

P/S 4,77

EV/EBITDA 13,39

EV/Revenue 6,00

ESG Scores

Total ESG 20,9

Environment 1,5

Social 15,1

Governance 5,8

Section 3

Earnings

Earnings metrics from company highlights and earnings datasets.

EPS estimate (current year) 22,41

Quarterly earnings growth 4,40%

Revenue TTM 37,22 Mld

Reported quarters 121

Section 4

Dividends & corporate actions

Dividend and split fields from fundamentals.

Dividend yield 2,92%

Forward annual div. yield 3,45%

Dividend per share 9,6600

Payout ratio 43,05%

Ex-dividend date 2025-08-22

Next dividend date 2026-06-05

Split factor 2:1

Last split date 1999-11-22

Section 5

Ownership / analyst view

Institutional ownership and analyst estimate fields when available.

Analyst

Analyst target price 311,46 $

Analyst rating 3.625

Ownership & short interest

Shares outstanding 538,36 Mln

Shares float 536,99 Mln

Institutional ownership 84,15%

Insider ownership 21,40%

Short ratio 4,66

Short % of float 2,36%

Details

Instrument metadata and source update timestamps.

Symbol AMGN

Name Amgen Inc

Asset type STOCK

Exchange NASDAQ

Currency USD

ISIN US0311621009

Country USA

Code + exchange AMGN.NASDAQ

Last price date 2026-05-08

Fundamentals updated 2026-05-08

Le informazioni fornite su questa piattaforma hanno solo scopo informativo e non devono essere considerate consulenza finanziaria o di investimento. Insightfolio non fornisce consulenza d'investimento, raccomandazioni personalizzate o indicazioni relative all'acquisto, alla detenzione o alla vendita di strumenti finanziari. Gli strumenti e i contenuti sono destinati esclusivamente a finalita educative e non sono adattati alle circostanze individuali, alle esigenze finanziarie o agli obiettivi personali.

Insightfolio non si assume alcuna responsabilita per l'accuratezza, la completezza o l'affidabilita delle informazioni presentate. Gli utenti sono gli unici responsabili della verifica delle informazioni e dell'assunzione di decisioni indipendenti basate sulla propria ricerca e su un'attenta valutazione. L'uso della piattaforma non deve sostituire la consulenza di professionisti finanziari qualificati.

Gli investimenti comportano rischi. Gli utenti devono essere consapevoli che il valore degli investimenti puo variare e che i rendimenti passati non sono indicativi di risultati futuri. Le decisioni di investimento devono basarsi sugli obiettivi finanziari personali, sulla tolleranza al rischio e su una valutazione indipendente delle informazioni rilevanti.

Insightfolio non approva ne garantisce l'idoneita di alcun prodotto finanziario, titolo o strategia specifica. Eventuali proiezioni, previsioni o scenari ipotetici presentati sulla piattaforma hanno solo scopo illustrativo e non costituiscono garanzia di risultati futuri.

Accedendo ai servizi, alle informazioni o ai contenuti offerti da Insightfolio, gli utenti riconoscono e accettano i presenti termini di esclusione di responsabilita. Se non accetti questi termini, ti invitiamo a non utilizzare la piattaforma.

Instrument logos provided by Elbstream.